N'-羟基-2,4-二甲基苯甲脒 | 52400-13-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N'-羟基-2,4-二甲基苯甲脒
• 英文名称: N'-hydroxy-2,4-dimethylbenzenecarboximidamide
• 英文别名: 2,4-dimethyl-benzamide oxime；asymm. m-Xylylsaeure-amidoxim；2,4-Dimethyl-benzamidoxim；2,4-Dimethyl-benzaldoxim；N'-Hydroxy-2,4-dimethylbenzimidamide
• CAS: 52400-13-2
• 化学式: C₉H₁₂N₂O
• 分子量: 164.207
• InChiKey: IFFWMMRYAJUJOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2925290090

反应信息

• 作为反应物：
  描述：

  N'-羟基-2,4-二甲基苯甲脒 生成 3-(2,4-dimethylphenyl)-5-phenyl-1,2,4-oxadiazole
  参考文献：
  名称：

  Oppenheimer, Chemische Berichte, 1889, vol. 22, p. 2445

  摘要：

  DOI：
• 作为产物：
  描述：

  2,4-二甲基苯甲腈 在 羟胺 作用下， 以 甲醇 为溶剂， 生成 N'-羟基-2,4-二甲基苯甲脒
  参考文献：
  名称：

  酰氧基am巨细胞病毒DNA聚合酶抑制剂的构效关系。

  摘要：

  本文描述了新型的巨细胞病毒DNA聚合酶抑制剂的结构活性关系，该抑制剂具有两个通过酰氧基oxy连接子连接的芳基。对其中末端基团不同的一系列类似物的研究表明，在先导化合物的2,4-二氯苯基周围有非常窄的SAR，但苯并噻唑环的各种替代物均具有活性。其中最引人注目的是化合物78的异恶唑环，与先导化合物相比，其效价提高了30倍。我们还描述了10个类似物的设计，合成和评估，其中酰氧基am连接基被等位基团修饰或替代。结构-活性关系研究确定了接头-NH2基团是关键的药效学元素。从头算分子轨道计算与对空间相互作用能的定性估计相结合，表明酰氧基am连接子的最低能构象具有扩展的平面CAr-C = NOC排列以及同平面或反平面NOCC（Ar'）安排。在三个酰氧基am的晶体结构中仅观察到反平面构象。在这些研究的基础上设计的最有效的连接基修饰化合物是氨基甲酸20 20，在巨细胞病毒DNA聚合酶抑制试验中，氨基甲酸am的含量约为对照酰氧基am

  DOI：

  10.1016/s0968-0896(99)00319-3

文献信息

• [EN] PIPERIDINYLPYRAZOLOPYRIMIDINONES AND THEIR USE<br/>[FR] PIPÉRIDINYLPYRAZOLOPYRIMIDINONES ET LEUR UTILISATION
  申请人：BAYER PHARMA AG

  公开号：WO2016071216A1

  公开（公告）日：2016-05-12

  The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is associated with a disease or medical intervention selected from the group consisting of heavy menstrual bleeding, postpartum hemorrhage, hemorrhagic shock, hemorrhagic cystitis, gastrointestinal hemorrhage, trauma, surgery, transplantation, stroke, liver diseases, hereditary angioedema, nosebleed, and synovitis and cartilage damage following hemarthrosis.

  本申请涉及新型取代哌啶基吡唑吡嘧啶酮，以及它们的制备方法，这些化合物可单独或组合使用于治疗和/或预防疾病的方法中，特别是用于治疗和/或预防患有或不患有基础遗传或获得性止血障碍的患者的急性和复发性出血，其中出血与从重经期出血、产后出血、出血性休克、出血性膀胱炎、胃肠道出血、创伤、手术、移植、中风、肝脏疾病、遗传性血管性水肿、鼻血、以及血液积聚后的滑膜炎和软骨损伤等一组疾病或医疗干预有关。
• [DE] PHENYLTHIOESSIGSÄURE-DERIVATE UND IHRE VERWENDUNG<br/>[EN] PHENYLTHIOACETIC ACID DERIVATIVES AND USE THEREOF<br/>[FR] DERIVES D'ACIDE PHENYLTHIOACETIQUE ET LEUR UTILISATION
  申请人：BAYER HEALTHCARE AG

  公开号：WO2005097784A1

  公开（公告）日：2005-10-20

  Die vorliegende Anmeldung betrifft neue Phenylthioessigsäure-Derivate der Formel (I), Verfahren zu ihrer Herstellung, ihre Verwendung zur Behandlung und/oder Prophylaxe von Krankheiten sowie ihre Verwendung zur Herstellung von Arzneimitteln zur Behandlung und/oder Prophylaxe von Krankheiten, vorzugsweise zur Behandlung und/oder Prävention kardiovaskulärer Erkrankungen, insbesondere von Dyslipidämien und Arteriosklerose. Die Verbindungen wirken als Modulatoren des PRAR-alpha Rezeptors.

  本申请涉及新的Phenylthioessigsäure衍生物的化学式(I)，其制备方法，其用于治疗和/或预防疾病以及用于制造用于治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病，特别是治疗和/或预防血脂异常和动脉粥样硬化。这些化合物作为PRAR-alpha受体的调节剂。
• Heterocyclic derivatives, process for their preparation and their
  申请人：Sanofi

  公开号：US05891893A1

  公开（公告）日：1999-04-06

  The invention relates to compounds of formula: ##STR1## in which: A is selected from O or S; B is selected from C or N; Z.sub.1 is selected from C.sub.1 -C.sub.4 alkylene or phenylene; Z.sub.2 is C.sub.1 -C.sub.4 alkylene; W is NR.sub.1 R.sub.2, in which R.sub.1 is selected from H or C.sub.1 -C.sub.4 alkyl and R.sub.2 is selected from H, C.sub.1 -C.sub.4 alkyl, CONQ.sub.1 Q.sub.2 or CSNQ.sub.1 Q.sub.2 in which Q.sub.1 and Q.sub.2 are independently selected from H or C.sub.1 -C.sub.4 alkyl, SO.sub.2 Q.sub.3 or COQ.sub.3 in which Q.sub.3 is C.sub.1 -C.sub.4 alkyl, COOQ.sub.4 in which Q.sub.4 is selected from C.sub.1 -C.sub.4 alkyl or benzyl, or R.sub.1 and R.sub.2 taken together with N form a saturated heterocycle, or W is selected from C.sub.1 -C.sub.4 alkoxy or thioalkoxy, CONQ.sub.1 Q.sub.2 or CSNQ.sub.1 Q.sub.2, pyridyl, imidazolyl or COOQ.sub.5 in which Q.sub.5 is C.sub.1 -C.sub.5 alkyl; R.sub.3 is not present when B is N, or is H, C.sub.1 -C.sub.8 alkyl or halogen; Ar.sub.1 is selected from optionally substituted phenyl, thienyl, furyl, indolyl, naphthyl or benzyl or Ar.sub.1 and R.sub.3 taken together form a phenylalkylene group; Ar.sub.2 is selected from pyrimidinyl, quinolyl, isoquinolyl, indolyl, isoindolyl or pyridyl, optionally substituted; as well as their salts.

  本发明涉及公式为：##STR1##的化合物，其中：A选自O或S; B选自C或N; Z.sub.1选自C.sub.1-C.sub.4烷基或苯基; Z.sub.2为C.sub.1-C.sub.4烷基; W为NR.sub.1R.sub.2，在其中R.sub.1选自H或C.sub.1-C.sub.4烷基，R.sub.2选自H、C.sub.1-C.sub.4烷基、CONQ.sub.1Q.sub.2或CSNQ.sub.1Q.sub.2，在其中Q.sub.1和Q.sub.2独立地选自H或C.sub.1-C.sub.4烷基、SO.sub.2Q.sub.3或COQ.sub.3，在其中Q.sub.3为C.sub.1-C.sub.4烷基、COOQ.sub.4在其中Q.sub.4选自C.sub.1-C.sub.4烷基或苄基，或R.sub.1和R.sub.2与N一起形成饱和的杂环，或W选自C.sub.1-C.sub.4烷氧基或硫代烷氧基、CONQ.sub.1Q.sub.2或CSNQ.sub.1Q.sub.2、吡啶基、咪唑基或COOQ.sub.5，在其中Q.sub.5为C.sub.1-C.sub.5烷基; 当B为N时R.sub.3不存在，否则为H、C.sub.1-C.sub.8烷基或卤素; Ar.sub.1选自可选取代的苯基、噻吩基、呋喃基、吲哚基、萘基或苄基，或Ar.sub.1和R.sub.3一起形成苯基烷基基团; Ar.sub.2选自嘧啶基、喹啉基、异喹啉基、吲哚基、异吲哚基或吡啶基，可选取代;以及它们的盐。
• Phenylthioacetic Acid Derivatives and Use Thereof
  申请人：Bischoff Hilmar

  公开号：US20080255202A1

  公开（公告）日：2008-10-16

  The present application relates to novel phenylthioacetic acid derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, in particular dyslipidaemias and arteriosclerosis.

  本申请涉及新型苯硫乙酸衍生物，其制备方法，以及它们用于治疗和/或预防疾病的用途，以及用于制备治疗和/或预防疾病的药物的用途，特别是用于治疗和/或预防心血管疾病，尤其是血脂异常和动脉硬化。
• Heterocyclic derivatives process for their preparation and their
  申请人：Sanofi

  公开号：US05891894A1

  公开（公告）日：1999-04-06

  The invention relates to compounds of formula: ##STR1## in which: A is selected from 0 or S; B is selected from C or N; Z.sub.1 is selected from C.sub.1 -C.sub.4 alkylene or phenylene; Z.sub.2 is C.sub.1 -C.sub.4 alkylene; W is NR.sub.1 R.sub.2, in which R.sub.1 is selected from H or C.sub.1 -C.sub.4 alkyl and R.sub.2 is selected from H, C.sub.1 -C.sub.4 alkyl, CONQ.sub.1 Q.sub.2 or CSNQ.sub.1 Q.sub.2 in which Q.sub.1 and Q.sub.2 are independently selected from H or C.sub.1 -C.sub.4 alkyl, SO.sub.2 Q.sub.3 or COQ.sub.3 in which Q.sub.3 is C.sub.1 -C.sub.4 alkyl, COOQ.sub.4 in which Q.sub.4 is selected from C.sub.1 -C.sub.4 alkyl or benzyl, or R.sub.1 and R.sub.2 taken together with N form a saturated heterocycle, or W is selected from C.sub.1 -C.sub.4 alkoxy or thioalkoxy, CONQ.sub.1 Q.sub.2 or CSNQ.sub.1 Q.sub.2, pyridyl, imidazolyl or COOQ.sub.5 in which Q.sub.5 is C.sub.1 -C.sub.5 alkyl; R.sub.3 is not present when B is N, or is H, C.sub.1 -C.sub.8 alkyl or halogen; Ar.sub.1 is selected from optionally substituted phenyl, thienyl, furyl, indolyl, naphthyl or benzyl or Ar.sub.1 and R.sub.3 taken together form a phenylalkylene group; Ar.sub.2 is selected from pyrimidinyl, quinolyl, isoquinolyl, indolyl, isoindolyl or pyridyl, optionally substituted; as well as their salts.

  本发明涉及以下式的化合物：##STR1## 其中：A选择为0或S；B选择为C或N；Z.sub.1选择为C.sub.1-C.sub.4烷基或苯基；Z.sub.2选择为C.sub.1-C.sub.4烷基；W为NR.sub.1R.sub.2，其中R.sub.1选择为H或C.sub.1-C.sub.4烷基，R.sub.2选择为H、C.sub.1-C.sub.4烷基、CONQ.sub.1Q.sub.2或CSNQ.sub.1Q.sub.2，其中Q.sub.1和Q.sub.2独立选择为H或C.sub.1-C.sub.4烷基、SO.sub.2Q.sub.3或COQ.sub.3，其中Q.sub.3为C.sub.1-C.sub.4烷基、COOQ.sub.4，其中Q.sub.4选择为C.sub.1-C.sub.4烷基或苄基，或R.sub.1和R.sub.2与N一起形成饱和杂环，或W选择为C.sub.1-C.sub.4烷氧基或硫代烷氧基、CONQ.sub.1Q.sub.2或CSNQ.sub.1Q.sub.2、吡啶基、咪唑基或COOQ.sub.5，其中Q.sub.5选择为C.sub.1-C.sub.5烷基；当B为N时，R.sub.3不存在，或为H、C.sub.1-C.sub.8烷基或卤素；Ar.sub.1选择为可选择取代的苯基、噻吩基、呋喃基、吲哚基、萘基或苄基，或Ar.sub.1和R.sub.3一起形成苯基烷基基团；Ar.sub.2选择为嘧啶基、喹啉基、异喹啉基、吲哚基、异吲哚基或吡啶基，可选择取代；以及它们的盐。